Quarterly ResultMay 14, 2026, 08:12 AM
Benitec Biopharma Q3 Net Loss $11.9M; BB-301 Shows Durable Responses
AI Summary
Benitec Biopharma reported a net loss of $11.9 million, or $(0.24) per share, for the third fiscal quarter ended March 31, 2026, an improvement from a $14.5 million loss in the prior year. The company provided a positive operational update on its BB-301 clinical study for OPMD, highlighting durable responses from low-dose treatment and further improvements with high-dose BB-301. Benitec is well-capitalized with $184.8 million in cash and plans to engage with the FDA mid-year to formalize the BB-301 pivotal study design.
Key Highlights
- BB-301 showed durable responses at 12 and 24 months with low dose.
- High dose BB-301 demonstrated further improved depth of response.
- Net loss for Q3 2026 was $11.9 million, down from $14.5 million YoY.
- Loss per share was $(0.24) for Q3 2026, compared to $(0.38) YoY.
- Total expenses decreased to $13.6 million from $15.3 million YoY.
- Cash and cash equivalents stood at $184.8 million as of March 31, 2026.
- Company plans FDA engagement mid-year for BB-301 pivotal study design.